interleukin-2
interleukin-2 is a biological therapy with 147 clinical trials. Currently 35 active trials ongoing. Historical success rate of 71.3%.
Success Metrics
Based on 57 completed trials
Phase Distribution
Phase Distribution
70
Early Stage
59
Mid Stage
11
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
67.1%
57 of 85 finished
32.9%
28 ended early
35
trials recruiting
147
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Therapy for Children With Advanced Stage Neuroblastoma
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Clinical Trials (147)
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Therapy for Children With Advanced Stage Neuroblastoma
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
CIML NK Cells With Venetoclax for AML
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
TIL Therapy in cSCC and MCC
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 147